- Where does etanercept sit in the treatment paradigm for patients with axial spondyloarthritis? (0:15)
- What were the aims of your recent analysis of data from studies evaluating the safety and efficacy of etanercept in the treatment of patients with axial spondyloarthritis? (1:14)
- What were the findings of the study and what factors determined an early response? (2:23)
- What are the implications of these findings for clinical practice? (4:19)
Disclosures: Xenofon Baralikos has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Axial Spondyloarthritis
Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
Denis Poddubnyy, ACR 2020 – Secukinumab for AxSpA Spinal Pain: SKIPPAIN Study
It was an absolute pleasure to discuss the 24-week results from the SKIPPAIN study (NCT03136861) with Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany ). The study, which is a phase IIIb trial, evaluated the efficacy and safety of secukinumab in reducing spinal pain and disease activity following a step-up dosing approach. His presentation entitled ‘Secukinumab Provides Significant […]
Anna Moltó, ACR 2020: TICOSPA Trial in Axial Spondyloarthritis
It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis. The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!